Genfit: upbeat after updated outlook
These decisions make the company eligible for a first milestone payment, and taking into account further payments from the launch of commercialization, it could receive a total of approximately 89 million euros by the end of next year.
Under its licensing agreement with Ipsen, Genfit is also eligible for double-digit royalties on sales of elafibranor in PBC, which Ipsen expects to peak at over 500 million euros a year.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction